Analysis of clinical effects and effects of Vepotolizumab/Urova

Polatuzumab/Polatuzumab is one of the important breakthroughs in the field of lymphoma treatment in recent years. It is an antibody drug conjugate (ADC). Its core mechanism is to precisely bind to the CD79b molecule on the surface of B cells through the antibody part, and then deliver the toxin into the tumor cells, releasing monomethyl auristatin E (MMAE), thereby inducing cell death. This "fixed-point blasting" method allows the drug to reduce some of the side effects of traditional chemotherapy while ensuring its efficacy.

In clinical application, velpotuzumab is mainly used to treat diffuse largeB-cell lymphoma (DLBCL; non-Hodgkin lymphoma). In studies and guidelines, it is often used in combination with drugs such as rituximab and bendamustine, especially in relapsed or refractory populations, showing better response rates. For newly diagnosed DLBCL patients, combination regimens have gradually been proven to increase the rate of complete remission. Compared with chemotherapy alone, ULOVA can delay disease progression without significantly increasing the toxic burden.

From the perspective of efficacy, the most outstanding value of vepotuzumab is that it breaks through the limitations of traditional treatment resistance. Relapsed or refractory DLBCL has always been a clinical problem, and patients often have limited options after multiple lines of treatment. The introduction of this drug provides new hope for this group. In real-world clinical applications, some patients are able to achieve long-term remission after taking the drug, which brings new possibilities for improving prognosis.

In terms of safety, common adverse reactions of vepotuzumab include hematological toxicities, such as neutropenia, anemia, and thrombocytopenia, as well as peripheral neuropathy and gastrointestinal discomfort. Most of these adverse effects are manageable and can be alleviated with dose adjustment and supportive care. Clinicians usually monitor the patient's basic condition when taking medication to balance efficacy and tolerability.

Reference materials:https://www.drugs.com/polivy.html